Deep Tech Startups

SynCardia manufactures the world's first commercially approved total artificial heart for patients with end-stage heart failure awaiting transplant. The company develops and delivers mechanical circulatory support devices as alternatives to heart transplantation for critically ill patients.

1 investor

Syndex develops mcPCR (methyl copying PCR), a proprietary platform technology that amplifies DNA while preserving methylation patterns, addressing the challenge of low DNA levels in clinical samples. The technology targets clinical applications including oncology and early cancer detection, residual disease and treatment monitoring, drug development, and chronic disease detection.

1 investor

Synergia Medical develops optoelectronic implantable medical devices, including its NAO.VNS vagus nerve stimulation system, which is undergoing First-In-Human clinical evaluation through the AURORA study. The company is based in Belgium.

1 investor

SynergyXR develops virtual and augmented reality tools that help professionals integrate XR technologies into their everyday work processes.

1 investor

Synex develops compact, portable technology that uses magnetic resonance spectroscopy to measure blood metabolites such as glucose and lactate non-invasively and in real time, without a needle prick. The company is building non-invasive health monitoring devices aimed at enabling predictive healthcare.

1 investor

Synfini provides AI-driven drug discovery collaboration services that help researchers advance targets and hits into optimized, patentable chemistry. The company offers a platform combining virtual screening, scaffold hopping, synthesis planning, and parallel library synthesis to accelerate early-stage drug discovery.

1 investor

Synova Life Sciences develops technology for biomedical applications, focusing on innovative solutions in the life sciences sector.

1 investor

Synovus Solutions designs and builds custom automated test systems (ATE) for product manufacturing, including hardware-in-the-loop simulation, machine vision measurement, and its Symplify framework. It also provides engineering consulting and LabVIEW development services to help teams build test systems.

1 investor

Synplexity produces large-scale, cost-effective gene libraries for synthetic biology applications using microreactor technology. The company serves researchers in drug discovery, protein engineering, and functional screening across life sciences and biotechnology.

1 investor

SynSense develops neuromorphic intelligence chips and vision systems for human-machine and brain-computer interfaces, optimizing for ultra-low power consumption and latency in edge computing applications.

1 investor

SynSense develops neuromorphic chips that integrate sensing and computing with ultra-low power and latency for AI edge computing, human-machine, and brain-computer interface applications. Through its group company iniVation, it also offers frame-based and bio-inspired vision systems.

1 investor

Synth-Med develops a drug delivery platform that uses red blood cells to encapsulate therapeutic payloads in nanoparticles and target hard-to-reach tissues, with a lead program delivering a memory-enhancing molecule to the brain for Alzheimer's and other neurodegenerative diseases. The company operates in the biotech and therapeutics sector.

1 investor

SynthBiome designs synthetic growth media that replicate the physiological conditions bacterial pathogens encounter in human infection sites, including media mimicking cystic fibrosis sputum and chronic wound environments. Its models serve researchers and clinical teams for drug development and antibiotic treatment selection.

1 investor

Synthio Chemicals develops advanced manufacturing processes for fine chemicals, using process intensification, scale-up, and automation to deliver scalable production processes for client firms. The company acts as a development partner offering consultations on custom chemical manufacturing.

1 investor

Syntropi provides rights-cleared, real-world video datasets for training frontier video and world models, sourcing long-form and egocentric footage through contracted contributors. It verifies and structures the footage via a proprietary ML pipeline, delivering training-ready datasets with clear provenance to AI model developers.

1 investor

SynVaccine develops technology for the computer-aided design and construction of viral genomes, applying synthetic and computational biology to create viral-based products such as vaccines and viral-based therapeutics. The company targets applications in human pharma and animal health.

1 investor

Systellar provides a design platform called synapse that enables model-based systems engineering for complex physical systems, offering unified workspace for design, requirements management, documentation, and workflow automation with version control and traceability capabilities.

1 investor

t1 is a cross-chain liquidity and interoperability protocol that uses trusted execution environments (TEEs) and real-time proving to enable composable applications across the EVM/Ethereum ecosystem. It provides developers with cross-chain composability, permissionless interop, and products such as an RTP bridge for faster, cheaper bridging.

1 investor

Tachyon develops particle accelerator technology and infrastructure at the frontier of applied physics. The company is building hardware and systems for advanced physics applications, with a team of scientists and engineers from SpaceX, national laboratories, and related deep tech organizations.

1 investor

Tackpoint manufactures bearings and bearing systems for applications in subsurface, surface, aerospace, and space environments. The company provides friction reduction solutions and anti-friction bearing systems to engineering-focused customers including oceanic explorers and aerospace companies.

1 investor

TactoTek provides design tools, reference designs, and technical resources for In-Mold Structural Electronics (IMSE) manufacturing, serving designers, engineering firms, and manufacturers across the product development lifecycle. The company offers digital tools, feature libraries, and knowledge bases to support the design and production of IMSE parts from concept to mass production.

1 investor

The company develops DNA aptamers—single-stranded oligonucleic acid therapeutics—using proprietary artificial base-pair technology for drug discovery and medical applications. The platform aims to create effective and safe pharmaceuticals that can be widely distributed, while also enabling applications in medical devices and diagnostics.

1 investor

Tagomics develops multimodal technologies for precision medicine and next-generation diagnostics. The company is based in Cambridge and focuses on improving patient outcomes through advanced diagnostic technologies.

1 investor

Anthropic is an AI company developing Claude, a large language model, and is building custom chips in-house to improve performance and efficiency of its AI models for customers.

1 investor